Cantor Fitzgerald last night upgraded Fulcrum Therapeutics (FULC) to Overweight from Neutral with a $10 price target Today’s share valuation is reflecting very little credit for pociredir, which is likely to have a role in a “very large” sickle cell disease market, the analyst tells investors in a research note. The firm says that with 100,000 U.S. patients, pociredir could be a drug to consider for many. Cantor says its physician feedback has been mixed, but still supports a role for pociredir.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- Oppenheimer biotech analyst holds an analyst/industry conference call
- Cautious Outlook for Fulcrum Therapeutics Amid Phase 1b Progress and Enrollment Uncertainties
- Hold Rating for Fulcrum Therapeutics Amid Promising Trials and Competitive Challenges
- Fulcrum Therapeutics Reports Q1 2025 Progress and Stability